Skip to main content
. Author manuscript; available in PMC: 2021 Mar 26.
Published in final edited form as: Blood Cancer Discov. 2020 Dec 23;2(2):135–145. doi: 10.1158/2643-3230.BCD-20-0161

Figure 1. Humanized scaffold system in NSG and NSG-SGM3 immunodeficient mice.

Figure 1

(A) Schematic representation of the in vivo protocol used for generating humanized scaffolds. Illustration was created with BioRender.com (B) Representative example of Immunofluorescence and H&E (Hematoxylin and eosin) staining for the scaffold retrieved following the xenotransplantation. H&E staining of a section of the engrafted scaffold shows multiple neutrophils with hypolobated nuclei (examples indicated with arrows), consistent with dysplasia in the granulocytic lineage. (C) Representative flow cytometry plot of the cells retrieved from the humanized scaffolds following the xenotransplantation. (D) Comparison of hCD45+ cells engraftment in humanized scaffolds retrieved from NSG and NSG-SGM3 mice. (E) Absolute cell counts of human myeloid (hCD45+hCD33+) cells retrieved from humanized scaffolds implanted in NSG and NSG-SGM3 mice. BM- Bone marrow cells, MSC- Mesenchymal stromal cells.